Attached files

file filename
EX-99.2 - APRIL 2011 INVESTOR PRESENTATION - QUESTCOR PHARMACEUTICALS INCdex992.htm
EX-99.1 - PRESS RELEASE - QUESTCOR PHARMACEUTICALS INCdex991.htm

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 4, 2011

 

 

QUESTCOR PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in Charter)

 

 

 

California   001-14758   33-0476164

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

1300 Kellogg Drive, Suite D, Anaheim, California   92807
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code: (714) 786-4200

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 2.02 Results of Operation and Financial Condition

On April 4, 2011, Questcor Pharmaceuticals, Inc. (the “Company”) issued a press release that provided preliminary operating metrics for the Company’s fiscal quarter ended March 31, 2011. A copy of the Company’s press release is furnished under this Item 2.02 and included as Exhibit 99.1 to this Current Report on Form 8-K.

 

Item 7.01 Regulation FD Disclosure

The press release also announced that the Company will make a presentation (the “Investor Presentation”) to certain members of the investment community and, in connection therewith, will provide updated information about the Company. A copy of the Investor Presentation is furnished under this Item 7.01 and included as Exhibit 99.2 to this Current Report on Form 8-K. The Investor Presentation will be made available on the Company’s website at www.questcor.com.

The Company will host a live webcast covering the Investor Presentation to be held on Tuesday, April 5, 2011, at 8:00 a.m. ET. To listen to the audio web cast of the Investor Presentation during or after the event, please visit www.questcor.com. The replay will be available for 90 days after the event.

In accordance with General Instruction B.2. of Form 8-K, the information in Item 2.02 and Item 7.01 of this Current Report on Form 8-K, including Exhibits 99.1 and 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

Item 9.01 Financial Statements and Exhibits

 

(d) Exhibits.

 

Exhibit No.    Description
99.1    Questcor Pharmaceuticals, Inc. press release dated April 4, 2011.
99.2    Questcor Pharmaceuticals, Inc. April 2011 Investor Presentation.

 

2


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: April 4, 2011   QUESTCOR PHARMACEUTICALS, INC.
    By:  

/s/ Michael Mulroy

     

Michael Mulroy, Chief Financial Officer &

General Counsel

 

3


EXHIBIT INDEX

 

Exhibit No.

  

Description

99.1    Questcor Pharmaceuticals, Inc. press release dated April 4, 2011.
99.2    Questcor Pharmaceuticals, Inc. April 2011 Investor Presentation.

 

4